Cargando…
Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD)
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920745/ https://www.ncbi.nlm.nih.gov/pubmed/35542995 http://dx.doi.org/10.14283/jpad.2022.28 |
| _version_ | 1784669194505158656 |
|---|---|
| author | Shuren, J. Doraiswamy, P. M. |
| author_facet | Shuren, J. Doraiswamy, P. M. |
| author_sort | Shuren, J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8920745 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89207452022-03-15 Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD) Shuren, J. Doraiswamy, P. M. J Prev Alzheimers Dis Point of View Springer International Publishing 2022-03-11 2022 /pmc/articles/PMC8920745/ /pubmed/35542995 http://dx.doi.org/10.14283/jpad.2022.28 Text en © Serdi and Springer Nature Switzerland AG 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Point of View Shuren, J. Doraiswamy, P. M. Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD) |
| title | Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD) |
| title_full | Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD) |
| title_fullStr | Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD) |
| title_full_unstemmed | Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD) |
| title_short | Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD) |
| title_sort | digital therapeutics for mci and alzheimer’s disease: a regulatory perspective — highlights from the clinical trials on alzheimer’s disease conference (ctad) |
| topic | Point of View |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920745/ https://www.ncbi.nlm.nih.gov/pubmed/35542995 http://dx.doi.org/10.14283/jpad.2022.28 |
| work_keys_str_mv | AT shurenj digitaltherapeuticsformciandalzheimersdiseasearegulatoryperspectivehighlightsfromtheclinicaltrialsonalzheimersdiseaseconferencectad AT doraiswamypm digitaltherapeuticsformciandalzheimersdiseasearegulatoryperspectivehighlightsfromtheclinicaltrialsonalzheimersdiseaseconferencectad |